Lorediplon
Lorediplon is a nonbenzodiazepine hypnotic drug that is being developed for the treatment of insomnia. It belongs to the class of pyrazolopyrimidine compounds and acts as a positive allosteric modulator of the GABA_A receptor.
Pharmacology[edit]
Lorediplon works by enhancing the effect of the neurotransmitter gamma-aminobutyric acid (GABA) at the GABA_A receptor, which results in sedative, anxiolytic, and muscle relaxant properties. This mechanism of action is similar to that of other nonbenzodiazepine hypnotics such as zolpidem and zaleplon.
Clinical Trials[edit]
Lorediplon has undergone several clinical trials to evaluate its efficacy and safety in the treatment of insomnia. These trials have shown that lorediplon can improve sleep onset and maintenance, with a favorable safety profile compared to traditional benzodiazepines.
Side Effects[edit]
Common side effects of lorediplon include drowsiness, dizziness, and headache. As with other hypnotics, there is a potential for dependence and withdrawal symptoms with long-term use.
Comparison with Other Hypnotics[edit]
Lorediplon is often compared to other nonbenzodiazepine hypnotics such as eszopiclone, zaleplon, and zolpidem. It is believed to have a longer half-life than some of these agents, which may make it more effective for maintaining sleep throughout the night.
Regulatory Status[edit]
As of the latest updates, lorediplon is still under investigation and has not yet received approval from major regulatory agencies such as the Food and Drug Administration (FDA) or the European Medicines Agency (EMA).
See Also[edit]
References[edit]
External Links[edit]
 | This medical article is a stub. You can help WikiMD by expanding the page. |
